Clinical Trial

HEC169096 in Participants With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-07-06; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2022-10-25
Trial Details
NCT Number NCT05451602
Lead Sponsor Sunshine Lake Pharma Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 456 participants
Start Date 2022-10-21
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-28